Legal & General Group’s Lipocine LPCN Stock Holding History

Legal & General Group’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-200	Closed	-$13K	–	3369
2017 Q1	$13K	Hold	200	–	–	﹤0.01%	3160
2016 Q4	$12K	Buy	+200	New	+$12.7K	﹤0.01%	3195

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Legal & General Group's LPCN Position: Q2 2017 in Review

Legal & General Group sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 200 shares — an estimated $13K sold.

Legal & General Group first reported a position in LPCN in Q4 2016 and held it in 2 quarters. The position peaked at $13K in Q1 2017. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

Legal & General Group reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
Legal & General Group sold 200 Lipocine shares in Q2 2017, an estimated $13K.
Legal & General Group first reported a position in Lipocine in Q4 2016 and held it in 2 quarters.
Legal & General Group's Lipocine position peaked at $13K in Q1 2017.
42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on Legal & General Group's 13F filing for Q2 2017, filed 3 Aug 2017.